August 5, 2025 – Talk Bio

Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion

2 days ago talkbio0Tagged Acute onset pain, Approved, Drug Development, Journavx, non-opioid pain drugs, Pain management, Peripheral neuropathic pain, Sodium Channel Blockers, United States Food and Drug Administration, VX-993

Vertex Pharmaceuticals; Journavx; VX-993; pain management; acute pain; phase 2 clinical trial; sodium channel inhibitor; non-opioid pain drugs; FDA approval; peripheral neuropathic pain; drug development

BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor

2 days ago talkbio0Tagged BioMarin, Drug Development, Immunogenicity (package insert), Palynziq, Phenylketonurias, R&D pipeline

BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity

Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats

2 days ago talkbio0Tagged Albert Bourla, Direct-to-Consumer, Drug Industry, drug price, Jr., Mehmet, Nation, negotiation, ounce, Pfizer, PhRMA, Policy, Pricing, Robert F. Kennedy, tariffs, Trump administration

Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA

Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

2 days ago talkbio0Tagged Agonist, Clinical Trials, competition, Danuglipron, Drug Development, Glucagon-Like Peptide 1, Injury of liver, lotiglipron, Obesity, PF-06954522, Pfizer

Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition

Imunon Halts COVID-19 Vaccine Program, Seeks Partner Due to Financial Struggles

2 days ago talkbio0Tagged Cash Crunch, COVID19 (disease), deprioritization, financial results, IMNN-101, Imunon, Partnership, Vaccines

Imunon; COVID-19 vaccine; IMNN-101; deprioritization; cash crunch; partnership; financial results

Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial

2 days ago talkbio0Tagged Clinical Research, Epilepsy, focal onset seizures, Praxis Precision Medicines, Radiant heater, Seizures, Sodium Channel Blockers, vormatrigine

Praxis Precision Medicines; vormatrigine; epilepsy; seizures; RADIANT study; focal onset seizures; Phase 2 trial; sodium channel blocker

Scientists Protest FDA’s Rejection of Replimune’s Tumor Destroying Therapy

2 days ago talkbio0Tagged Clinical Trials, Drug Approval, Heterogeneity, IGYNTE, melanoma, Oncolytic Immunotherapy, Rejection, Replimune, RETINITIS PIGMENTOSA 1, scientist protest, United States Food and Drug Administration

Replimune; RP1; FDA rejection; oncolytic immunotherapy; melanoma; clinical trial; IGYNTE study; scientist protest; drug approval; patient heterogeneity

Praxis touts ‘best-in-disease’ epilepsy data, but shares dip

3 days ago talkbio0Tagged anti-seizure medication, Clinical Research, Clinical Trials, Epilepsy, focal onset seizures, Market, Praxis Precision Medicines, Radiant heater, Seizures, vormatrigine

Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market